4b4a3828-d808-4d25-a06c-b738fd8daacb
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 78.0862422997947
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.280
- UV_RESPONSE_DN+0.240
- PANCREAS_BETA_CELLS+0.220
- APICAL_SURFACE+0.200
- ALLOGRAFT_REJECTION+0.190
- NOTCH_SIGNALING+0.150
- ESTROGEN_RESPONSE_EARLY+0.110
- ANDROGEN_RESPONSE+0.100
- HEDGEHOG_SIGNALING+0.100
- IL6_JAK_STAT3_SIGNALING+0.100
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.640
- MYC_TARGETS_V2-0.600
- MYC_TARGETS_V1-0.550
- MTORC1_SIGNALING-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.440
- DNA_REPAIR-0.420
- GLYCOLYSIS-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- E2F_TARGETS-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NJ-A55A-01A-11R-A262-07 | — | cohortA1 | 0.859 |
| 2 | MDT-AP-3062 | Med | Medulloblastoma | 0.849 |
| 3 | AUR-AER7-TTP1-A-1-0-R-A741-41 | — | D | 0.836 |
| 4 | TCGA-AC-A3OD-01B-06R-A22O-07 | — | D | 0.830 |
| 5 | SRR6013520 | — | cohortA1 | 0.828 |
| 6 | TCGA-AC-A3QQ-01B-06R-A22O-07 | — | D | 0.826 |
| 7 | BS_QEYPFYHD | Med | Medulloblastoma | 0.820 |
| 8 | s0122234 | — | — | 0.819 |
| 9 | bae6fdb5-9df3-433c-9a4c-e5c159a62bc6 | — | — | 0.818 |
| 10 | TCGA-CR-7388-01A-11R-2016-07 | — | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.070 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.040 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |